[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
1. Yamanegi K, Tang S, Zheng ZM: Kaposi's sarcoma-associated herpesvirus K8beta is derived from a spliced intermediate of K8 pre-mRNA and antagonizes K8alpha (K-bZIP) to induce p21 and p53 and blocks K8alpha-CDK2 interaction. J Virol; 2005 Nov;79(22):14207-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is a lymphotropic DNA tumor virus that induces Kaposi's sarcoma and AIDS-related primary effusion lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol Methods. 2000 Mar;85(1-2):203-14 [10716353.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2000 Nov;74(22):10612-22 [11044105.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):200-5 [11036071.001]
  • [Cites] J Virol. 2001 Feb;75(3):1487-506 [11152521.001]
  • [Cites] RNA. 2001 Jun;7(6):806-18 [11421359.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5512-9 [11463833.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Methods. 2002 Feb;26(2):162-9 [12054893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2805-14 [12393792.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):951-7 [12419238.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):1-3 [12559168.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • [Cites] J Virol. 2003 May;77(10):5578-88 [12719550.001]
  • [Cites] Rev Med Virol. 2003 May-Jun;13(3):173-84 [12740832.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] J Virol. 2003 Sep;77(17):9652-61 [12915577.001]
  • [Cites] J Virol. 2004 Mar;78(5):2609-14 [14963167.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Feb;5(2):89-99 [15040442.001]
  • [Cites] J Mol Biol. 2004 Apr 9;337(5):1091-108 [15046980.001]
  • [Cites] J Biomed Sci. 2004 May-Jun;11(3):278-94 [15067211.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):3304-15 [15210863.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32170-80 [15161914.001]
  • [Cites] Nucleic Acids Res. 1979 Sep 11;7(1):179-92 [386279.001]
  • [Cites] Nature. 1989 Nov 16;342(6247):243-7 [2812024.001]
  • [Cites] Cell. 1990 Oct 5;63(1):109-18 [2208274.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2411-4 [7852296.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28995-9003 [7499432.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 May 16;334(20):1292-7 [8609946.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):3012-22 [8649413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15081-5 [8986767.001]
  • [Cites] EMBO J. 1997 Feb 17;16(4):826-33 [9049311.001]
  • [Cites] RNA. 1997 Jul;3(7):764-78 [9214659.001]
  • [Cites] J Virol. 1997 Dec;71(12):9096-107 [9371566.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):919-32 [9536098.001]
  • [Cites] J Virol. 1998 Aug;72(8):6725-31 [9658120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] J Virol. 1999 Mar;73(3):1909-17 [9971770.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Mol Biol Cell. 1999 Mar;10(3):515-24 [10069800.001]
  • [Cites] J Gen Virol. 1999 Mar;80 ( Pt 3):557-61 [10091993.001]
  • [Cites] Genes Dev. 1999 Apr 1;13(7):851-63 [10197985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] RNA. 2000 Sep;6(9):1197-211 [10999598.001]
  • (PMID = 16254356.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC010357-06; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA Precursors; 0 / RNA, Viral; EC 3.1.26.4 / Ribonuclease H
  • [Other-IDs] NLM/ PMC1280184
  •  go-up   go-down


2. Boulanger E, Meignin V, Afonso PV, Duprez R, Oksenhendler E, Agbalika F, Gessain A: Extracavitary tumor after primary effusion lymphoma: relapse or second distinct lymphoma? Haematologica; 2007 Sep;92(9):1275-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracavitary tumor after primary effusion lymphoma: relapse or second distinct lymphoma?
  • HHV-8-associated solid lymphomas which develop in extracavitary sites during the course of primary effusion lymphoma (PEL) could represent the relapse of original PEL tumors in different anatomical sites, or newly occurring distinct HHV-8-associated lymphomas, such as multicentric Castleman disease-related microlymphomas.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma / complications. Lymphoma, AIDS-Related / complications. Neoplasm Recurrence, Local / complications. Pleural Effusion, Malignant / complications

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768127.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


3. Honda M, Morikawa T, Yamaguchi Y, Tani M, Yamaguchi K, Iijima K, Akishita M, Fukayama M, Ouchi Y: [A case of a primary effusion lymphoma in the elderly]. Nihon Ronen Igakkai Zasshi; 2009;46(6):551-6
Genetic Alliance. consumer health - Primary effusion lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a primary effusion lymphoma in the elderly].
  • We report a 90-year-old man who was given a diagnosis of pleural effusion lymphoma (PEL) based on the detailed immunochemical and DNA analyses of the pleural effusion.
  • He was transferred to our hospital with fever and massive pleural effusion.
  • A cytological examination of the pleural effusion revealed class 5 atypical lymphocytes with a high nucleus/cytoplasm ratio.
  • The origin of the atypical cells could not be determined by flow cytometry of the pleural effusion, which only suggested the existence of inflammatory changes.
  • We conducted immunochemical staining after making a cell block from the effusion sample.
  • PEL is a rare type of lymphoma confined to the body cavities without any prominent tumor mass, and its pathogenesis is related to HHV-8 infection.
  • PEL develops mostly in immunocompromised patients, such as those with AIDS.
  • We should therefore also consider the possibility of PEL in elderly patients presenting with pleural effusion of unknown origin.
  • [MeSH-major] Lymphoma, Primary Effusion / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139653.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Nair P, Pan H, Stallings RL, Gao SJ: Recurrent genomic imbalances in primary effusion lymphomas. Cancer Genet Cytogenet; 2006 Dec;171(2):119-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent genomic imbalances in primary effusion lymphomas.
  • Primary effusion lymphomas (PEL) form a subset of AIDS-related lymphomas and usually have a poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Mar 1;101(5):1956-61 [12406869.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):305-19 [16075461.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Hematol J. 2001;2(3):172-9 [11920242.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Med Genet. 1999 Jul;36(7):511-7 [10424810.001]
  • (PMID = 17116491.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NCI NIH HHS / CA / CA096512-02; United States / NCI NIH HHS / CA / R01 CA124332-01A2; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NCI NIH HHS / CA / R01 CA132637
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS165930; NLM/ PMC2799290
  •  go-up   go-down


5. Pantanowitz L, Wu Z, Dezube BJ, Pihan G: Extracavitary primary effusion lymphoma of the anorectum. Clin Lymphoma Myeloma; 2005 Sep;6(2):149-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracavitary primary effusion lymphoma of the anorectum.
  • We report a case of an extracavitary primary effusion lymphoma occurring in the anorectum of a patient with advanced acquired immune deficiency syndrome.
  • The morphology, null cell immunophenotype, and acquisition of plasma cell markers in this case are typical of the so-called solid variant of primary effusion lymphoma.
  • Lymphoma cells in this case were shown to be co-infected with human herpesvirus-8 and Epstein-Barr virus.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. HIV Infections / pathology. Herpesvirus 4, Human. Herpesvirus 8, Human. Lymphoma, AIDS-Related / pathology. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231856.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Jiang Y, Xu D, Zhao Y, Zhang L: Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One; 2008 Feb 06;3(2):e1569
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
  • The majority of AIDS-associated primary effusion lymphoma (PEL) are co-infected with both KSHV and EBV.
  • Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2003 Jun 5;310(2):199-206 [12781707.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Gen Virol. 2003 Aug;84(Pt 8):1941-9 [12867624.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(12):4085-9 [2987963.001]
  • [Cites] EMBO J. 1986 Dec 1;5(12):3243-9 [3028777.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1652-6 [2830625.001]
  • [Cites] EMBO J. 1989 May;8(5):1447-53 [2548844.001]
  • [Cites] EMBO J. 1989 Jun;8(6):1819-26 [2548857.001]
  • [Cites] J Virol. 1990 Jan;64(1):313-21 [2152819.001]
  • [Cites] J Virol. 1990 Mar;64(3):1143-55 [2154599.001]
  • [Cites] J Virol. 1990 Mar;64(3):1227-32 [2154606.001]
  • [Cites] J Virol. 1990 Jun;64(6):2560-8 [2159531.001]
  • [Cites] J Virol. 1990 Aug;64(8):3753-9 [2164595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9459-63 [2174563.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] J Virol. 2007 Sep;81(17):9279-91 [17596302.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1929-38 [8114724.001]
  • [Cites] J Virol. 1994 May;68(5):3354-63 [8151794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2748-59 [8654372.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31799-802 [8943219.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] J Virol. 2000 Mar;74(6):2550-7 [10684269.001]
  • [Cites] Oncogene. 1991 Feb;6(2):195-204 [1847997.001]
  • [Cites] Genes Dev. 1991 Dec;5(12B):2441-54 [1661258.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] J Virol. 1993 Aug;67(8):4651-8 [8392605.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1617-26 [10022850.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Aug;73(8):6551-8 [10400751.001]
  • [Cites] J Virol. 1999 Sep;73(9):7271-7 [10438815.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(13):8493-505 [15956592.001]
  • [Cites] J Virol. 2005 Nov;79(21):13298-309 [16227252.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2000 Dec;74(24):11800-10 [11090180.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Jan;75(1):341-50 [11119603.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2388-99 [11160742.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Oct;75(19):9446-57 [11533207.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Virol. 2001 Nov;75(21):10334-47 [11581402.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Virol. 2002 Feb;76(3):998-1003 [11773375.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6438-42 [11741976.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Virology. 2002 Aug 1;299(2):301-14 [12202233.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • (PMID = 18253508.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108951; United States / NCRR NIH HHS / RR / RR15635; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / CA108951; United States / NIAID NIH HHS / AI / AI59132
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2215330
  •  go-up   go-down


7. Brimo F, Michel RP, Khetani K, Auger M: Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer; 2007 Aug 25;111(4):224-33
Genetic Alliance. consumer health - Primary effusion lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis.
  • BACKGROUND: Primary effusion lymphoma (PEL) is a human herpes virus-8 (HHV-8)-associated and very rare type of lymphoma usually confined to the body cavities and commonly observed in human immunodeficiency virus (HIV)-infected patients.
  • CONCLUSIONS: Cytomorphologically, PEL exhibits features bridging large cell immunoblastic and anaplastic large cell lymphoma.
  • [MeSH-major] Herpesviridae Infections / diagnosis. Herpesviridae Infections / pathology. Herpesvirus 8, Human / isolation & purification. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Humans. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554754.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


8. Carbone A, Cesarman E, Gloghini A, Drexler HG: Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS; 2010 Feb 20;24(4):479-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.
  • Primary effusion lymphoma (PEL) is a very rare subgroup of B-cell lymphomas presenting as pleural, peritoneal and pericardial neoplastic effusions in the absence of a solid tumor mass or recognizable nodal involvement.
  • Fourteen continuous cell lines have been established from the malignant effusions of patients with AIDS-associated and non-AIDS-associated PEL.
  • The PEL cell lines display unique features and are clearly distinct from other lymphoma cell lines.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Trends Genet. 1998 Apr;14(4):144-50 [9594662.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Adv Cancer Res. 1998;75:57-86 [9709807.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]
  • [Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]
  • [Cites] Trends Microbiol. 1999 May;7(5):196-200 [10354594.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Adv Virus Res. 1999;52:139-232 [10384236.001]
  • [Cites] J Med Virol. 1999 Aug;58(4):394-401 [10421407.001]
  • [Cites] J Infect Dis. 1999 Sep;180(3):824-8 [10438372.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4984-9 [10519412.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):415-9 [15621832.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leuk Res. 2005 May;29(5):545-55 [15755507.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):165-72 [12215016.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):833-40 [12802923.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):913-6 [12808126.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]
  • [Cites] Blood. 1993 Jul 1;82(1):247-61 [8100721.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2794-804 [9184224.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Radiology. 1997 Nov;205(2):459-63 [9356629.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2430-40 [16508017.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):335-47 [16604559.001]
  • [Cites] J Pathol. 2006 Aug;209(4):464-73 [16741895.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:185-209 [17089798.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Acta Haematol. 2007;117(3):132-44 [17135726.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1285-92 [17368758.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] PLoS Pathog. 2007 Sep 7;3(9):1348-60 [17907806.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Blood. 2008 Jan 1;111(1):320-7 [17890449.001]
  • [Cites] J Cell Sci. 2008 Feb 15;121(Pt 4):450-7 [18211958.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]
  • (PMID = 20051807.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA068939; United States / NCI NIH HHS / CA / R01 CA103646; United States / NCI NIH HHS / CA / R01CA068939; United States / NCI NIH HHS / CA / R01CA103646
  • [Publication-type] Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS492494; NLM/ PMC3740588
  •  go-up   go-down


9. Yanagisawa Y, Sato Y, Asahi-Ozaki Y, Ito E, Honma R, Imai J, Kanno T, Kano M, Akiyama H, Sata T, Shinkai-Ouchi F, Yamakawa Y, Watanabe S, Katano H: Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol; 2006 Aug;209(4):464-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma.
  • Lymphoma usually forms solid tumours in patients, and high expression levels of adhesion molecules are observed in these tumours.
  • However, Kaposi's sarcoma-associated herpesvirus (KSHV)-related primary effusion lymphoma (PEL) does not form solid tumours and adhesion molecule expression is suppressed in the cells.
  • Inoculation of a KSHV-associated PEL cell line into the peritoneal cavity of severe combined immunodeficiency mice resulted in the formation of effusion and solid lymphomas in the peritoneal cavity.
  • Proteomics using two-dimensional difference gel electrophoresis and DNA microarray analyses identified 14 proteins and 105 genes, respectively, whose expression differed significantly between effusion and solid lymphomas.
  • Among these, coronin 1A, an actin-binding protein, was identified as a molecule showing high expression in solid lymphoma by both DNA microarray and proteomics analyses.
  • Moreover, KSHV-encoded lytic proteins, including viral interleukin-6, were highly expressed in effusion lymphoma compared with solid lymphoma.
  • These data demonstrate that effusion and solid lymphomas possess distinctive gene and protein expression profiles in our mouse model, and suggest that differences in gene and protein expression between effusion and solid lymphomas may be associated with the formation of effusion lymphoma or invasive features of solid lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, AIDS-Related / genetics. Sarcoma, Kaposi / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA, Viral / analysis. Electrophoresis, Gel, Two-Dimensional. Gene Expression Profiling. Humans. Lymphocyte Function-Associated Antigen-1 / genetics. Mice. Mice, SCID. Models, Animal. Oligonucleotide Array Sequence Analysis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / virology. Proteomics. Reverse Transcriptase Polymerase Chain Reaction. Viral Proteins / analysis

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16741895.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Lymphocyte Function-Associated Antigen-1; 0 / Viral Proteins
  •  go-up   go-down


10. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol; 2005 Jul 1;23(19):4372-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
  • PURPOSE: Primary effusion lymphoma (PEL) is a rare high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
  • To date, no prognostic factor has been identified in this subset of lymphoma.
  • CONCLUSION: Based on a retrospective series of 28 patients, two prognostic factors were identified as being independently associated with impaired clinical outcome in HIV-related PEL--(1) a poor performance status and (2) the absence of HAART before PEL diagnosis.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Herpesvirus 8, Human. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome. Adult. Aged. Ascites / complications. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pericardial Effusion / complications. Pleural Effusion, Malignant / complications. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome


11. Mylona E, Baraboutis IG, Georgiou O, Rondogianni D, Lekakis LJ, Papastamopoulos V, Apostolidis I, Skoutelis AT: Solid variant of primary effusion lymphoma in successfully treated HIV infection: a case report. Int J STD AIDS; 2008 Aug;19(8):570-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid variant of primary effusion lymphoma in successfully treated HIV infection: a case report.
  • Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, mainly met in severely immunocompromised, HIV-positive patients.
  • PEL is aetiologically related to human herpes virus-8 (HHV-8) and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumour mass.
  • Recently, cases of HIV-positive patients with HHV-8-positive solid tissue lymphomas, not associated with an effusion, have been reported (solid variant of PEL).
  • We report a case of an HIV-positive patient with a typical solid variant of PEL without effusion.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. HIV Infections / drug therapy. Herpesvirus 8, Human. Lymphoma, AIDS-Related / pathology. Lymphoma, Primary Effusion / pathology


12. Casper C, Wald A: The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr Top Microbiol Immunol; 2007;312:289-307
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma.
  • Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease are all associated with KSHV infection.
  • Although the incidence of KS has declined dramatically in areas with access to highly active antiretroviral therapy, it remains the most common AIDS-associated malignancy in the developed world and is one of the most common cancers in developing nations.
  • [MeSH-major] Antiviral Agents / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. Lymphoma, AIDS-Related / drug therapy. Sarcoma, Kaposi / prevention & control
  • [MeSH-minor] Animals. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA Replication / drug effects. Disease Models, Animal. Humans. Pleural Effusion, Malignant / drug therapy

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089802.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K23 AI054162; United States / NIAID NIH HHS / AI / U19 AI31448
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antiviral Agents
  • [Number-of-references] 72
  •  go-up   go-down


13. Tanaka PY, Atala MM, Pereira J, Caterino-de-Araujo A: Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART. J Clin Virol; 2009 Jan;44(1):84-5
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART.
  • Primary effusion lymphoma (PEL) is a rare type of lymphoma related to herpesvirus-8 (HHV-8), and considered an AIDS-defining condition.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. HIV Long-Term Survivors. Heart Neoplasms / secondary. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis


14. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections
  • [MeSH-minor] Animals. Antigens, Viral / physiology. Apoptosis. Burkitt Lymphoma / pathology. Cell Line, Tumor / transplantation. Herpesvirus 4, Human / isolation & purification. Herpesvirus 4, Human / pathogenicity. Mice. Mice, Inbred NOD. Mice, SCID. Necrosis. Nuclear Proteins / physiology. Random Allocation. Signal Transduction / drug effects. Specific Pathogen-Free Organisms. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


15. Carbone A, Gloghini A: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol; 2005 Sep;130(5):662-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: from pathogenesis to pathology.
  • The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.
  • (2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.
  • The pathological heterogeneity of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas (AIDS-NHL) reflects the heterogeneity of their associated molecular lesions.
  • In AIDS-BL, the molecular lesions involve activation of cMYC, inactivation of P53, and infection with Epstein-Barr virus (EBV).
  • AIDS-IBL infected with EBV are characterised by frequent expression of latent membrane protein 1--an EBV oncoprotein.
  • The biological heterogeneity of AIDS-NHL is highlighted by their histogenetic differences.
  • Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8)-associated lymphomas, which often develop in persons with advanced AIDS, present predominantly as PEL.
  • (2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi


16. Sarek G, Järviluoma A, Ojala PM: KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood; 2006 Jan 15;107(2):725-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas.
  • Kaposi sarcoma herpesvirus (KSHV) infection is consistently associated with primary effusion lymphomas (PELs) that are non-Hodgkin lymphomas of B-cell origin.
  • [MeSH-major] Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / antagonists & inhibitors. Herpesvirus 8, Human / metabolism. Lymphoma, AIDS-Related / metabolism. Sarcoma, Kaposi / metabolism. Viral Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160006.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclins; 0 / HHV8-Vcyc protein, Human herpesvirus 8; 0 / Viral Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


17. Youngster I, Vaisben E, Cohen H, Nassar F: An unusual cause of pleural effusion. Age Ageing; 2006 Jan;35(1):94-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of pleural effusion.
  • Primary effusion lymphoma (PEL) is a unique clinicopathological entity associated with human herpesvirus-8 (HHV-8) infection, occurring almost exclusively in human immunodeficiency virus (HIV)-infected individuals.
  • We report a rare case of HHV-8-negative PEL in an HIV-negative elderly patient who presented with pleural effusion.
  • [MeSH-major] Lymphoma, AIDS-Related / complications. Pleural Effusion, Malignant / etiology

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364944.001).
  • [ISSN] 0002-0729
  • [Journal-full-title] Age and ageing
  • [ISO-abbreviation] Age Ageing
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Navarro WH, Kaplan LD: AIDS-related lymphoproliferative disease. Blood; 2006 Jan 1;107(1):13-20
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoproliferative disease.
  • Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.
  • Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.
  • Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099881.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


19. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, Zhao L, Trivedi P, Jones C, Zhang L: Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol; 2007 Jun;81(11):6068-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.
  • The majority of AIDS-associated primary effusion lymphomas (PEL) are latently infected with both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV).
  • Both LMP-1 and K-RTA are expressed during primary infection by EBV of KSHV latency cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] Gene. 2003 Oct 16;316:137-41 [14563560.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46335-42 [15322136.001]
  • [Cites] Int J Cancer. 1977 Jan;19(1):27-33 [188769.001]
  • [Cites] J Virol. 1980 Nov;36(2):506-18 [6253674.001]
  • [Cites] J Virol. 1985 Sep;55(3):710-20 [2991591.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] Virology. 1985 Mar;141(2):221-34 [3002016.001]
  • [Cites] J Virol. 1986 Apr;58(1):233-7 [3005654.001]
  • [Cites] J Gen Virol. 1987 Jun;68 ( Pt 6):1575-86 [2438376.001]
  • [Cites] Virology. 1987 Jul;159(1):161-5 [3037776.001]
  • [Cites] J Virol. 1990 Apr;64(4):1855-8 [2157069.001]
  • [Cites] J Virol. 1990 May;64(5):2126-34 [2157875.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] J Virol. 1990 Jul;64(7):3407-16 [2352328.001]
  • [Cites] J Virol. 1990 Nov;64(11):5441-7 [2170681.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1107-15 [1648447.001]
  • [Cites] J Virol. 1991 Dec;65(12):6765-71 [1658373.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] J Virol. 1993 Aug;67(8):4651-8 [8392605.001]
  • [Cites] J Virol. 1993 Nov;67(11):6768-77 [8411380.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Virol. 2002 Feb;76(3):998-1003 [11773375.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):437-42 [11752411.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Virology. 1997 Jul 21;234(1):1-13 [9234942.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] J Virol. 2000 Mar;74(6):2550-7 [10684269.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6438-42 [11741976.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] J Virol. 1994 May;68(5):3354-63 [8151794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Virol. 1995 Jul;69(7):4390-8 [7769701.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Oct;11(10):1241-5 [8573381.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Virology. 1996 Sep 1;223(1):29-40 [8806537.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Sep;73(9):7271-7 [10438815.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(23):12987-95 [15542650.001]
  • [Cites] J Virol. 2004 Dec;78(23):13028-36 [15542654.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Nov;79(22):14383-91 [16254372.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9163-9 [16469740.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] BMC Microbiol. 2002 Jul 23;2:20 [12137568.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Virology. 2002 Aug 1;299(2):301-14 [12202233.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6337-44 [12414666.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1905-12 [12411306.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • [Cites] J Virol. 2003 Apr;77(8):5000-7 [12663807.001]
  • (PMID = 17376914.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI060547; United States / NCI NIH HHS / CA / R01 CA108951; United States / NIAID NIH HHS / AI / R21AI59132; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20RR15635; United States / NIAID NIH HHS / AI / U54 AI057160; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / R01CA108951
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1900272
  •  go-up   go-down


20. Lacoste V, Nicot C, Gessain A, Valensi F, Gabarre J, Matta H, Chaudhary PM, Mahieux R: In primary effusion lymphoma cells, MYB transcriptional repression is associated with v-FLIP expression during latent KSHV infection while both v-FLIP and v-GPCR become involved during the lytic cycle. Br J Haematol; 2007 Aug;138(4):487-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In primary effusion lymphoma cells, MYB transcriptional repression is associated with v-FLIP expression during latent KSHV infection while both v-FLIP and v-GPCR become involved during the lytic cycle.
  • Primary effusion lymphoma (PEL) is a rare, distinct subtype of non-Hodgkin lymphoma, which is associated with Kaposi sarcoma-associated herpesvirus (KSHV) infection.
  • [MeSH-major] Gene Expression Regulation, Viral. Genes, myb. Herpesvirus 8, Human / physiology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology. Sarcoma, Kaposi / virology

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659053.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA124621; United States / NCI NIH HHS / CA / CA85177
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Immediate-Early Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-myb; 0 / Receptors, G-Protein-Coupled; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins
  •  go-up   go-down


21. Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R, Tirelli U: Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn; 2005 Feb;7(1):17-27
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.
  • Kaposi's sarcoma-associated herpesvirus (KSHV), also termed human herpesvirus type 8, is consistently identified in Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.
  • Here we report four cases of KSHV-bearing solid lymphomas that occurred in AIDS patients (cases 1 to 3) and in a human immunodeficiency virus (HIV)-seronegative person (case 4).
  • The patients did not develop a lymphomatous effusion.
  • Epstein-Barr virus was detected in two of the HIV-related cases.
  • To investigate the relationship of these disorders to PEL and to other AIDS-associated diffuse large cell lymphomas, KSHV-positive solid lymphomas were tested for the expression of a set of genes that were previously shown by gene profiling analysis to define PEL tumor cells.
  • The results showed that expression of this set of genes in KSHV-positive lymphomas is similar to that of PEL but distinct from KSHV-negative AIDS-associated diffuse large cell lymphomas.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1208-16 [10524521.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]
  • [Cites] AIDS. 2000 Aug 18;14(12):1675-88 [10985303.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):290-6 [15507667.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1202-16 [4031967.001]
  • [Cites] N Engl J Med. 1993 Feb 4;328(5):327-35 [8093551.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4955-67 [8262038.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • (PMID = 15681470.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA037295; United States / NCI NIH HHS / CA / R37 CA037295; United States / NCI NIH HHS / CA / CA-37295
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1876263
  •  go-up   go-down


22. Singh AS, Dave DJ, Thanvi S, Atre DA, Parikh P, Patel NH: Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma. Indian J Med Sci; 2006 Sep;60(9):380-4
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma.
  • Primary cardiac lymphomas are rare lesions in children with acquired immunodeficiency syndrome (AIDS).
  • They usually present with congestive cardiac failure, pericardial effusion or tamponade, arrhythmias, with predominant systemic 'B' symptoms and often with widespread extranodal involvement.
  • The clinical profile and operative and pathological findings of a 4-year-old boy with AIDS-associated Burkitt's lymphoma of the heart presenting with acute right heart failure and fatal secondary pulmonary hypertension is reported.
  • [MeSH-major] Burkitt Lymphoma / complications. Heart Neoplasms / complications. Hypertension, Pulmonary / etiology. Lymphoma, AIDS-Related / complications


23. El-Salem M, Raghunath PN, Marzec M, Liu X, Kasprzycka M, Robertson E, Wasik MA: Activation of mTORC1 signaling pathway in AIDS-related lymphomas. Am J Pathol; 2009 Aug;175(2):817-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of mTORC1 signaling pathway in AIDS-related lymphomas.
  • Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma.
  • These cases represented a diverse spectrum of histological types of non-Hodgkin lymphoma (24 cases) and classic Hodgkin lymphoma (five cases).
  • We also found that in B-cell lines that represent diffuse large B-cell lymphoma, Burkitt lymphoma, Epstein-Barr virus-infected lymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and, seemingly, phosphoinositide 3 kinases suppressed mTORC1 activation, in particular when these inhibitors were used in combination.
  • These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or, possibly, upstream activators of the mTORC1 pathway.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4070-80 [12145207.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21960-71 [12668683.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]
  • [Cites] Biochimie. 2003 Aug;85(8):763-9 [14585543.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Pediatr Transplant. 2004 Jun;8(3):243-8 [15176961.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):14846-9 [1869521.001]
  • [Cites] J Biol Chem. 1992 Apr 25;267(12):8613-9 [1569106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9107-11 [1409610.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15900-5 [8340414.001]
  • [Cites] J Biol Chem. 1993 Nov 15;268(32):24442-8 [8226994.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5918-25 [8119935.001]
  • [Cites] J Immunol. 1994 Jun 1;152(11):5429-37 [8189062.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]
  • [Cites] Immunol Lett. 1999 Jun 1;68(2-3):301-9 [10424436.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19937-47 [15760907.001]
  • [Cites] Nephrol Dial Transplant. 2005 Aug;20(8):1748-51 [15919698.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):e67-72 [16632009.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26904-13 [16816403.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6347-60 [17041621.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] Lab Invest. 2007 Jan;87(1):29-39 [17075574.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1267-71 [17524950.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Transplant Proc. 2007 Jul-Aug;39(6):2036-7 [17692685.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2181-9 [18025151.001]
  • [Cites] Transpl Int. 2008 Jun;21(6):605-8 [18282244.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]
  • [Cites] Transplantation. 2003 May 27;75(10):1710-7 [12777861.001]
  • (PMID = 19608873.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089194; United States / NIDCR NIH HHS / DE / R01 DE017337; United States / NCI NIH HHS / CA / R01-CA89194; United States / NIDCR NIH HHS / DE / R01-DE-017337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Phospho-Specific; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 17885-08-4 / Phosphoserine; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2716976
  •  go-up   go-down


24. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.
  • Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology


25. Simonelli C, Tedeschi R, Gloghini A, Talamini R, Bortolin MT, Berretta M, Spina M, Morassut S, Vaccher E, De Paoli P, Carbone A, Tirelli U: Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol; 2009 May;81(5):888-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
  • Patients with Multicentric Castleman Disease and HHV-8-related lymphoma diagnosed and treated from April 1987 to June 2004 were included in the study.
  • Nine patients with Multicentric Castleman disease, and 16 with HHV-8-related lymphomas (13 primary effusion lymphomas and 3 solid lymphomas), were diagnosed and treated out of 327 HIV-related non-Hodgkin's lymphomas.
  • Nine patients with primary effusion lymphoma were treated with a CHOP-like regimen (Cyclophosphamide, Prednisone anthracyclines, Vinca alkaloids, Bleomycin, Etoposide) and HAART; 1 with etoposide and HAART, 1 with HAART alone.
  • The patients with solid lymphoma underwent CHOP-like chemotherapy.
  • Patients with Multicentric Castleman disease showed lower median values of HHV-8 viral load and longer overall survival compared with HHV-8-related lymphomas.
  • In the univariate analysis, HHV-8-related lymphoma, HHV-8 viral load >40,000 cp/ml and performance status >2 were associated with an increased risk of death.
  • Multivariate analysis confirmed the diagnosis of lymphoma as an independent predictor of shorter survival.
  • [MeSH-major] HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 8, Human / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / complications. Viral Load
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA, Viral / blood. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / virology. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / virology. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult


26. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res; 2008 Mar 1;68(5):1436-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3.
  • We analyzed five primary "endemic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV(+) primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell lymphomas (DLBCL) for expression of EBV-encoded miRNAs.
  • Primary unmanipulated type I BLs and EBV(+) PELs expressed high levels of BART2 miRNA, whereas DLBCLs expressed both BART2 and BHRF1-3 species.
  • EBV-encoded miRNAs are expressed in primary lymphomas classically linked to the virus and are associated with the viral latency status.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Microbiol. 2000;54:19-48 [11018123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 [17911266.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1098-104 [12219084.001]
  • [Cites] J Gen Virol. 2003 Apr;84(Pt 4):949-57 [12655096.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Virology. 2004 May 20;323(1):141-52 [15165826.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30219-27 [15150261.001]
  • [Cites] RNA. 2004 Aug;10(8):1165-73 [15272116.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8058-62 [1325642.001]
  • [Cites] J Virol. 1993 Jun;67(6):3182-90 [8388496.001]
  • [Cites] J Virol. 1995 Feb;69(2):1132-41 [7815492.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1493-501 [7632957.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1408-14 [9416698.001]
  • [Cites] Science. 1998 Apr 10;280(5361):248-53 [9535648.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2009-21 [9625760.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Science. 2005 Apr 22;308(5721):557-60 [15845854.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):682-6 [15931223.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):343-51 [16000952.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Development. 2005 Nov;132(21):4645-52 [16224044.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Mamm Genome. 2006 Mar;17(3):189-202 [16518686.001]
  • [Cites] Curr Opin Genet Dev. 2006 Apr;16(2):203-8 [16503132.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):2966-74 [16503368.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] J Virol. 2007 Sep;81(18):9967-75 [17626073.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • (PMID = 18316607.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA082274; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BHRF1 protein, Human herpesvirus 4; 0 / CXCL11 protein, human; 0 / Chemokine CXCL11; 0 / MicroRNAs; 0 / Oligonucleotides, Antisense; 0 / Viral Proteins; EC 3.1.- / Ribonucleases
  • [Other-IDs] NLM/ NIHMS191351; NLM/ PMC2855641
  •  go-up   go-down


27. Cai Q, Verma SC, Lu J, Robertson ES: Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res; 2010;78:87-142
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.
  • Kaposi's Sarcoma-associated Herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus,and is associated with the pathogenesis of Kaposi's sarcoma and two lymphoproliferative disorders known to occur frequently in AIDS patients-primary effusion lymphoma and multicentric Castleman disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1151-7 [10666184.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):213-24 [10670545.001]
  • [Cites] J Virol. 2000 Mar;74(6):2867-75 [10684303.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7 [10733899.001]
  • [Cites] Mol Med. 1998 Jun;4(6):402-12 [10780883.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2179-83 [10854238.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):2029-38 [10900042.001]
  • [Cites] J Virol. 2000 Sep;74(17):8194-201 [10933732.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Immunity. 2000 Sep;13(3):365-74 [11021534.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8254-63 [11027294.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):239-47 [11089981.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] Virology. 2000 Dec 5;278(1):60-74 [11112482.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] Virology. 2001 Aug 15;287(1):62-70 [11504542.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33805-11 [11448967.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Gen Virol. 2001 Oct;82(Pt 10):2393-404 [11562533.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):23-9 [11786394.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1226-34 [11801659.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Virology. 2001 Dec 20;291(2):241-59 [11878894.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] J Virol. 2002 May;76(9):4390-400 [11932406.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1535-45 [12075072.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Virol. 2002 Sep;76(17):8797-807 [12163600.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31863-7 [10542211.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6097-102 [10626797.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):72-84 [14729610.001]
  • [Cites] Herpes. 2003 Dec;10(3):72-7 [14759339.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):211-27 [14996505.001]
  • [Cites] FASEB J. 2004 Mar;18(3):422-7 [15003988.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):1-12 [15031665.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] J Mol Med (Berl). 2004 Apr;82(4):223-31 [14991150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Curr Opin Infect Dis. 2004 Feb;17(1):53-7 [15090892.001]
  • [Cites] Blood. 2004 May 1;103(9):3465-73 [14726403.001]
  • [Cites] J Virol. 2004 Jun;78(12):6389-98 [15163732.001]
  • [Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Nat Rev Microbiol. 2004 Aug;2(8):656-68 [15263900.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):322-30 [15197489.001]
  • [Cites] Lancet. 2004 Aug 28-Sep 3;364(9436):740-1 [15337387.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Virology. 2004 Oct 10;328(1):7-18 [15380353.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):390-6 [15368522.001]
  • [Cites] Annu Rev Med. 2001;52:453-70 [11160789.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):15-23 [11158202.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1112-5 [11167749.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):499-506 [11172090.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2345-52 [11160738.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):187-98 [11252894.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:906-12 [11268420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13427-32 [11154704.001]
  • [Cites] Arch Virol. 2001;146(2):403-13 [11315648.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3436-44 [11313469.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):499-516 [11313008.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):245-57 [11325605.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):833-43 [11336706.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Dermatol Sci. 2001 Jul;26(3):182-93 [11390203.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] Traffic. 2001 Jun;2(6):375-84 [11389765.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):505-13 [11418689.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Hum Virol. 2001 Mar-Apr;4(2):62-73 [11437316.001]
  • [Cites] J Virol. 2001 Aug;75(16):7572-82 [11462029.001]
  • [Cites] J Virol. 2005 Aug;79(16):10138-46 [16051806.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4840-3 [16145154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12885-90 [16120683.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1110-7 [16043440.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]
  • [Cites] Trends Biochem Sci. 2005 Nov;30(11):630-41 [16236519.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Nat Immunol. 2006 Jan;7(1):33-9 [16311601.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Virol. 2006 Feb;80(3):1385-92 [16415016.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] Immunity. 2002 Aug;17(2):143-55 [12196286.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:187-201 [12224509.001]
  • [Cites] J Virol. 2002 Oct;76(20):10320-31 [12239308.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Virol. 2002 Dec;76(23):11880-8 [12414930.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] Curr Biol. 2002 Nov 19;12(22):1928-33 [12445386.001]
  • [Cites] AIDS. 2002 Dec 6;16(18):2473-8 [12461423.001]
  • [Cites] Trends Cell Biol. 2003 Jan;13(1):7-12 [12480335.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7397-405 [12486118.001]
  • [Cites] J Virol. 2003 Mar;77(6):3878-81 [12610165.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9283-9 [12645526.001]
  • [Cites] J Virol. 2003 May;77(10):5578-88 [12719550.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):129-35 [12769790.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1463-70 [12771415.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1485-91 [12771417.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52406-11 [14561765.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] Eur J Med Res. 1998 Oct 14;3(10):461-4 [9753702.001]
  • [Cites] DNA Cell Biol. 1998 Sep;17(9):735-42 [9778032.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] J Virol. 1999 Feb;73(2):1438-46 [9882349.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Crit Rev Oncog. 1998;9(2):107-24 [9973245.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] J Hum Virol. 1998 Mar-Apr;1(3):207-13 [10195244.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5704-9 [10318948.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):201-9 [10343071.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):231-9 [10343074.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):5722-30 [10364323.001]
  • [Cites] J Virol. 1999 Jul;73(7):6006-14 [10364352.001]
  • [Cites] J Virol. 1999 Aug;73(8):6646-60 [10400762.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] AIDS. 1999 Jul 9;13(10):1165-76 [10416519.001]
  • [Cites] J Virol. 1999 Sep;73(9):7334-42 [10438822.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):827-40 [10499921.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Oct;78(20):11108-20 [15452231.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):45093-101 [15304516.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2903-11 [15231571.001]
  • [Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]
  • [Cites] J Clin Lab Immunol. 1983 Sep;12(1):1-10 [6355477.001]
  • [Cites] Lancet. 1984 Mar 3;1(8375):478-80 [6142209.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1318-20 [6145025.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6333-8 [3022918.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72 [1693429.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74 [1567395.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Medicine (Baltimore). 1993 Jul;72(4):245-61 [8341141.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Cell Biol. 1995 Aug;130(3):507-18 [7542657.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Nov 18;346(8986):1360-1 [7475785.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):200-3 [8567117.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):450-5 [8618237.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):858-61 [8826812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] AIDS. 1996 Sep;10(10):1101-5 [8874626.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Virol. 1996 Nov;70(11):8151-4 [8892944.001]
  • [Cites] Cell. 1996 Nov 1;87(3):447-58 [8898198.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1963-73 [16794734.001]
  • [Cites] J Virol. 2006 Aug;80(16):7965-75 [16873253.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):456-62 [16894293.001]
  • [Cites] J Virol. 2006 Sep;80(18):8909-19 [16940503.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):659-62 [17001705.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2516-24 [16810301.001]
  • [Cites] J Virol. 2006 Nov;80(21):10772-86 [16928766.001]
  • [Cites] J Virol. 2006 Nov;80(21):10802-12 [16956952.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Mol Immunol. 2007 Jan;44(1-3):11-22 [16905191.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:101-36 [17089795.001]
  • [Cites] J Gen Virol. 2006 Dec;87(Pt 12):3529-38 [17098967.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1550-8 [17047149.001]
  • [Cites] J Virol. 2007 Mar;81(5):2449-58 [17151100.001]
  • [Cites] J Virol. 2007 Mar;81(5):2401-17 [17151125.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):245-58 [17349582.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):391-401 [17457345.001]
  • [Cites] PLoS Pathog. 2007 Mar;3(3):e44 [17397260.001]
  • [Cites] J Virol. 2007 Aug;81(15):7941-59 [17507466.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):7003-10 [17638913.001]
  • [Cites] J Virol. 2007 Sep;81(18):9825-37 [17626102.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]
  • [Cites] J Virol. 2007 Oct;81(19):10413-23 [17634230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16287-92 [17909182.001]
  • [Cites] Cell Host Microbe. 2007 Aug 16;2(2):106-18 [18005725.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] J Virol. 1997 Jun;71(6):4187-92 [9151804.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):748-50 [9191012.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] J Virol. 1997 Aug;71(8):5894-904 [9223479.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20313-6 [9252331.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] J Pathol. 1997 Jul;182(3):262-5 [9349227.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1517-22 [9403701.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):395-7 [9498490.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] Science. 1998 Apr 10;280(5361):248-53 [9535648.001]
  • [Cites] Nat Med. 1998 Apr;4(4):435-40 [9546789.001]
  • [Cites] J Virol. 1998 Jun;72(6):4980-8 [9573267.001]
  • [Cites] Trends Genet. 1998 Apr;14(4):144-50 [9594662.001]
  • [Cites] J Virol. 1998 Jul;72(7):5433-40 [9620998.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):65-71 [9709306.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5219-28 [9710606.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] RNA. 2010 Aug;16(8):1540-58 [20566670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13069-74 [20615981.001]
  • [Cites] J Virol. 2010 Oct;84(19):9718-32 [20660191.001]
  • [Cites] J Virol. 2010 Nov;84(21):11134-44 [20719954.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:330-63 [14481196.001]
  • [Cites] J Virol. 2004 Dec;78(24):14033-8 [15564510.001]
  • [Cites] Cancer Invest. 2004;22(5):774-86 [15581058.001]
  • [Cites] J Virol. 2005 Jan;79(2):800-11 [15613308.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] J Virol. 2005 Feb;79(3):1397-408 [15650166.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1310-8 [15471957.001]
  • [Cites] J Virol. 2005 Feb;79(4):2637-42 [15681465.001]
  • [Cites] Science. 2005 Feb 4;307(5710):739-41 [15692053.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2067-75 [15688008.001]
  • [Cites] J Virol. 2005 Apr;79(8):4952-64 [15795281.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):771-7 [15854912.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(13):8493-505 [15956592.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Virol. 2005 Aug;79(15):9912-25 [16014952.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):156-63 [16014885.001]
  • [Cites] Retrovirology. 2005;2:9 [15713234.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2430-40 [16508017.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] Mol Immunol. 2006 Apr;43(10):1665-75 [16442624.001]
  • [Cites] J Virol. 2006 Apr;80(8):4068-78 [16571823.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1139-44 [16603514.001]
  • [Cites] J Virol. 2006 May;80(10):4833-46 [16641275.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1264-73 [16604194.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2717-26 [16418726.001]
  • [Cites] J Virol. 2006 Jun;80(11):5273-82 [16699007.001]
  • [Cites] J Virol. 2006 Jun;80(11):5371-82 [16699017.001]
  • [Cites] J Virol. 2006 Jun;80(12):6165-70 [16731955.001]
  • [Cites] J Virol. 2006 Jul;80(13):6534-52 [16775340.001]
  • [Cites] J Virol. 2006 Jul;80(14):7037-51 [16809309.001]
  • [Cites] Virology. 2008 Feb 5;371(1):139-54 [17964626.001]
  • [Cites] EMBO J. 2008 Feb 20;27(4):654-66 [18219272.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1751-9 [18339855.001]
  • [Cites] J Virol. 2008 Apr;82(8):4184-9 [18272573.001]
  • [Cites] AIDS. 2008 May 11;22(8):937-45 [18453853.001]
  • [Cites] J Virol. 2008 Jul;82(13):6734-46 [18417561.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4640-8 [18559509.001]
  • [Cites] J Virol. 2008 Sep;82(17):8771-9 [18579585.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4227-34 [18757778.001]
  • [Cites] J Virol. 2009 Apr;83(7):3342-64 [19158252.001]
  • [Cites] J Virol. 2009 May;83(10):4895-911 [19279100.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Jun;329(3):1142-7 [19258523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 26;106(21):8683-8 [19429708.001]
  • [Cites] BioDrugs. 2009;23(2):69-75 [19489649.001]
  • [Cites] J Virol. 2009 Jul;83(14):7129-41 [19439469.001]
  • [Cites] PLoS Pathog. 2009 Jul;5(7):e1000512 [19593382.001]
  • [Cites] J Virol. 2009 Aug;83(16):8163-72 [19493995.001]
  • [Cites] Virchows Arch. 2009 Aug;455(2):159-70 [19484260.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000606 [19798430.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000616 [19816565.001]
  • [Cites] Neoplasia. 2009 Dec;11(12):1272-84 [20019835.001]
  • [Cites] J Virol. 2010 Feb;84(3):1334-47 [19906914.001]
  • [Cites] Genes Dev. 2010 Jan 15;24(2):195-205 [20080955.001]
  • [Cites] Nat Cell Biol. 2010 Feb;12(2):193-9 [20081837.001]
  • [Cites] PLoS Pathog. 2010 Jan;6(1):e1000742 [20126446.001]
  • [Cites] J Virol. 2010 Mar;84(5):2188-99 [19923183.001]
  • [Cites] J Virol. 2010 Mar;84(5):2318-30 [20032179.001]
  • [Cites] PLoS Pathog. 2010 Feb;6(2):e1000777 [20169190.001]
  • [Cites] J Virol. 2010 Mar;84(6):2697-706 [20071580.001]
  • [Cites] PLoS One. 2010;5(3):e9720 [20300531.001]
  • [Cites] Oncogene. 2010 Mar 25;29(12):1835-44 [20023696.001]
  • [Cites] J Gen Virol. 2010 May;91(Pt 5):1138-49 [20089804.001]
  • [Cites] J Virol. 2010 May;84(10):5229-37 [20219912.001]
  • [Cites] Nat Cell Biol. 2010 May;12(5):513-9 [20418869.001]
  • [Cites] Virology. 2010 Jul 20;403(1):92-102 [20451233.001]
  • [Cites] Biochem Biophys Res Commun. 2010 Jun 4;396(3):608-13 [20417616.001]
  • [Cites] Free Radic Biol Med. 2010 Aug 1;49(3):383-91 [20441790.001]
  • (PMID = 21040832.001).
  • [ISSN] 1557-8399
  • [Journal-full-title] Advances in virus research
  • [ISO-abbreviation] Adv. Virus Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA091792; United States / NIDCR NIH HHS / DE / DE014136; United States / NIDCR NIH HHS / DE / R01 DE014136; United States / NCI NIH HHS / CA / R00 CA126182-04; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / K99 CA126182; United States / NIAID NIH HHS / AI / AI067037; United States / NCI NIH HHS / CA / R00 CA126182; United States / NCI NIH HHS / CA / CA126182-03; United States / NIAID NIH HHS / AI / R01 AI067037; United States / NIDCR NIH HHS / DE / R01 DE017338; United States / NCI NIH HHS / CA / CA126182; United States / NCI NIH HHS / CA / R00 CA126182-03; United States / NIDCR NIH HHS / DE / DE17338; United States / NCI NIH HHS / CA / CA126182-04; United States / NCI NIH HHS / CA / CA072510
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS309404; NLM/ PMC3142360
  •  go-up   go-down


28. Rappocciolo G, Hensler HR, Jais M, Reinhart TA, Pegu A, Jenkins FJ, Rinaldo CR: Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J Virol; 2008 May;82(10):4793-806
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN.
  • Human herpesvirus 8 (HHV-8) is the etiological agent of Kaposi's sarcoma, primary effusion lymphoma, and some forms of multicentric Castleman's disease.
  • HHV-8 could also infect and replicate in B-cell lines transduced to express full-length DC-SIGN but not in B-cell lines transduced to express DC-SIGN lacking the transmembrane domain, demonstrating that the entry of HHV-8 into B cells is related to DC-SIGN-mediated endocytosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jun 16;14(9):1123-33 [10894276.001]
  • [Cites] J Virol. 2008 Feb;82(3):1570-80 [18045938.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3537-40 [11574569.001]
  • [Cites] Immunity. 2002 Jan;16(1):135-44 [11825572.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2118-26 [11859097.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2634-43 [11884427.001]
  • [Cites] Blood. 2002 May 1;99(9):3360-6 [11964304.001]
  • [Cites] J Pathol. 2002 Dec;198(4):511-6 [12434421.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] Nat Rev Immunol. 2003 Sep;3(9):697-709 [12949494.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] Virology. 2004 Jan 5;318(1):17-23 [14972530.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Trends Microbiol. 2004 Jul;12(7):337-45 [15223061.001]
  • [Cites] J Immunol. 1974 Aug;113(2):608-16 [4602663.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8356-60 [1518869.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Infect Dis. 1996 Nov;174(5):1101-5 [8896516.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):147-53 [9006331.001]
  • [Cites] Lancet. 1997 Mar 1;349(9052):609-11 [9057733.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] J Virol. 1998 Oct;72(10):8143-9 [9733855.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] J Virol. 2005 Nov;79(22):14383-91 [16254372.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] Cell. 2000 Mar 3;100(5):575-85 [10721994.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3931-41 [16547227.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] PLoS Pathog. 2006 Jul;2(7):e70 [16839201.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1078-88 [16991082.001]
  • [Cites] Virology. 2006 Oct 10;354(1):7-14 [16889811.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • (PMID = 18337571.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082053; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / R01 CA 82053; United States / NIAID NIH HHS / AI / U01 AI 35041
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Cell Adhesion Molecules; 0 / DC-specific ICAM-3 grabbing nonintegrin; 0 / DNA, Viral; 0 / Histocompatibility Antigens Class I; 0 / Lectins, C-Type; 0 / Receptors, Cell Surface; 0 / Receptors, Virus; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2346758
  •  go-up   go-down


29. Kanno T, Sato Y, Nakamura T, Sakamoto K, Sata T, Katano H: Genotypic and clinicopathological characterization of Kaposi's sarcoma-associated herpesvirus infection in Japan. J Med Virol; 2010 Mar;82(3):400-6
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is related causally to Kaposi's sarcoma, primary effusion lymphoma, and a subset of cases of multicentric Castleman's disease.
  • As the numbers of acquired immunodeficiency syndrome (AIDS) patients have increased, KSHV-associated diseases have also increased in Japan.
  • In the present study, the clinicopathological characteristics of 75 samples, comprising 68 cases of Kaposi's sarcoma, 5 cases of primary effusion lymphoma, and 5 cases of multicentric Castleman's disease were investigated.
  • All fifty-two of the AIDS-associated Kaposi's sarcoma cases were males, whereas 7 of the 13 non-AIDS-associated Kaposi's sarcoma cases were females.
  • The mean age of patients with AIDS-associated Kaposi's sarcoma or primary effusion lymphoma was 46 years, whereas the mean age of patients with non-AIDS-associated Kaposi's sarcoma or primary effusion lymphoma was 71.8 and 97.5, respectively.
  • Genotypes A and C of KSHV were detected in both AIDS- and non-AIDS-associated Kaposi's sarcoma.
  • Genotype A was detected more frequently in AIDS-associated cases than non-AIDS-associated cases, suggesting that genotype C is broadly distributed in Japan, and genotype A spreads among AIDS patients.
  • Genotype D was detected only in non-AIDS-associated Kaposi's sarcoma.
  • These data confirmed the difference between AIDS- and non-AIDS-associated KSHV diseases with regard to age of onset, gender, and genotypes in Japan. J. Med. Virol.
  • [MeSH-major] Giant Lymph Node Hyperplasia / pathology. Herpesviridae Infections / pathology. Herpesvirus 8, Human / isolation & purification. Lymphoma, Primary Effusion / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087946.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


30. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood; 2009 Feb 5;113(6):1213-24
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system).
  • Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease.
  • These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells.
  • EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression.
  • (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
  • [MeSH-major] Gammaherpesvirinae / pathogenicity. HIV-1 / pathogenicity. Herpesviridae Infections / virology. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955561.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents
  • [Number-of-references] 162
  •  go-up   go-down


31. Sarek G, Ojala PM: p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle; 2007 Sep 15;6(18):2205-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV infection is the causative agent in three different tumor types: Kaposi's sarcoma, a plasmablastic variant of multicentric Castelman's disease and an AIDS-related form of B cell lymphoproliferative disorder called primary effusion lymphoma (PEL).
  • PEL manifests as an effusion malignancy in Kaposi's sarcoma patients with advanced AIDS, but also occurs in HIV-negative individuals.
  • [MeSH-major] Herpesvirus 8, Human / pathogenicity. Lymphoma, AIDS-Related / therapy. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / therapy. Sarcoma, Kaposi / virology. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890905.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 66
  •  go-up   go-down


32. Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol; 2008 Jan;140(1):13-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review looks at the current state of knowledge on primary effusion lymphoma (PEL) and other Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV8)-associated lymphomas.
  • In 1995, KSHV DNA sequences were identified within a distinct subgroup of acquired immunodeficiency syndrome-related non-Hodgkin lymphomas localized in body cavities and presenting as pleural, peritoneal and pericardial lymphomatous effusions.
  • KSHV/HHV8 infection is also in multicentric Castleman disease-associated plasmablastic lymphoma.
  • [MeSH-major] Herpesviridae Infections. Herpesvirus 8, Human. Lymphoma / virology
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / therapy. Lymphoma, AIDS-Related / virology. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991301.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


33. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
  • The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.
  • The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Clin (Barc). 2000 Jan 15;114(1):19-21 [10782456.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] Med Trop (Mars). 1999;59(4 Pt 2):499-502 [10901854.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]
  • [Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90 [11897040.001]
  • [Cites] East Afr Med J. 2000 Aug;77(8):435-9 [12862069.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] East Afr Med J. 1966 Jul;43(7):274-83 [5911333.001]
  • [Cites] Br Med Bull. 1971 Jan;27(1):14-20 [5100946.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):186-9 [6893012.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24 [6278823.001]
  • [Cites] East Afr Med J. 1982 Apr;59(4):256-60 [7140611.001]
  • [Cites] Ann Trop Paediatr. 1984 Jun;4(2):83-5 [6083750.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1865-73 [2004300.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Curr Opin Oncol. 1994 Sep;6(5):489-91 [7827151.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):48-53 [9044509.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1364-71 [9949180.001]
  • [Cites] Bull Cancer. 1999 Jun;86(6):529-36 [10417426.001]
  • [Cites] J Pak Med Assoc. 1999 Jan;49(1):11-5 [10463009.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S63-7 [15622604.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S90-6 [15622607.001]
  • [Cites] East Afr Med J. 2004 Aug;81(8):384-7 [15622930.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53 [16091262.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1291-9 [17487381.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):345-9 [18201268.001]
  • [Cites] Malays J Pathol. 1999 Jun;21(1):45-50 [10879278.001]
  • (PMID = 18577266.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2438337
  •  go-up   go-down


34. Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, Kato-Stankiewicz J, Nelson CG, Vieira J, Tamanoi F, Chanda SK, Sun R: Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog; 2007 Mar;3(3):e44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To systematically evaluate the cellular signals regulating this reactivation process in Kaposi sarcoma-associated herpesvirus, the effects of 26,000 full-length cDNA expression constructs on viral reactivation were individually assessed in primary effusion lymphoma-derived cells that harbor the latent virus.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Virol. 2001;146(2):403-13 [11315648.001]
  • [Cites] J Virol. 2001 Jun;75(11):5240-51 [11333906.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] Cell Signal. 2001 Nov;13(11):777-85 [11583913.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;947:117-23 [11795259.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Development. 2003 Jan;130(1):45-55 [12441290.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(10):3723-7 [2187191.001]
  • [Cites] Drugs. 1990 Apr;39(4):597-638 [2161731.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] J Neurosci. 1996 Nov 1;16(21):6784-94 [8824319.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):321-9 [12612580.001]
  • [Cites] Immunol Rev. 2003 Aug;194:29-38 [12846805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):685-98 [15632069.001]
  • [Cites] Science. 2005 Feb 4;307(5710):739-41 [15692053.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2005 Nov;79(21):13538-47 [16227274.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1139-44 [16603514.001]
  • [Cites] J Virol. 1999 Dec;73(12):9849-57 [10559297.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1841-8 [10595913.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] J Virol. 2000 Apr;74(8):3659-67 [10729142.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5781-8 [11059774.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36269-76 [12865432.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12153-8 [14514886.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):362-74 [15129648.001]
  • [Cites] Circulation. 2004 Jun 22;109(24):3035-41 [15173033.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(14):6127-39 [15226417.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5227-41 [15122343.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7439-46 [15492268.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Feb;76(2):782-5 [218219.001]
  • [Cites] Rev Infect Dis. 1982 Sep-Oct;4(5):1048-61 [6293034.001]
  • [Cites] EMBO J. 1989 Jun;8(6):1819-26 [2548857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11883-8 [8876232.001]
  • [Cites] Clin Transplant. 1996 Oct;10(5):429-31 [8930456.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Gene. 1997 Jan 31;185(1):11-7 [9034307.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] J Virol. 1997 Aug;71(8):5894-904 [9223479.001]
  • [Cites] AIDS. 1997 Sep;11(11):1327-32 [9302441.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1998 Oct;72(10):7978-84 [9733836.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 20;251(2):648-52 [9792828.001]
  • [Cites] Cell. 1998 Nov 13;95(4):521-30 [9827804.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Am J Ophthalmol. 1999 Mar;127(3):329-39 [10088745.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(23):13381-90 [15542692.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] Oncogene. 2000 Dec 18;19(55):6503-13 [11175366.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1441-3 [11238880.001]
  • (PMID = 17397260.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA032737; United States / NCI NIH HHS / CA / CA83525; United States / NCI NIH HHS / CA / CA 32737; United States / NIDCR NIH HHS / DE / R01 DE014153; United States / NCI NIH HHS / CA / CA91791; United States / NIDCR NIH HHS / DE / DE14153; United States / NCI NIH HHS / CA / R01 CA091791
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Proto-Oncogene Protein c-ets-1; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases
  • [Other-IDs] NLM/ PMC1839163
  •  go-up   go-down


35. Chang PC, Fitzgerald LD, Van Geelen A, Izumiya Y, Ellison TJ, Wang DH, Ann DK, Luciw PA, Kung HJ: Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res; 2009 Jul 15;69(14):5681-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) has been linked to the development of Kaposi's sarcoma, a major AIDS-associated malignancy, and to hematologic malignancies, including primary effusion lymphoma and multicentric Castleman's disease.

  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40463-70 [11013263.001]
  • [Cites] Virology. 2009 Apr 25;387(1):76-88 [19269659.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):1112-20 [11867539.001]
  • [Cites] Genes Dev. 2002 Apr 15;16(8):919-32 [11959841.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1785-92 [14742721.001]
  • [Cites] J Virol. 2004 Jul;78(14):7299-310 [15220403.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38325-30 [15247271.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Genes Dev. 1996 Aug 15;10(16):2067-78 [8769649.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):83-90 [9934688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4366-78 [10330177.001]
  • [Cites] J Virol. 2004 Dec;78(24):13637-52 [15564474.001]
  • [Cites] J Virol. 2005 Jan;79(1):245-56 [15596820.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):929-37 [15882967.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] EMBO J. 2005 Sep 21;24(18):3279-90 [16107876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16055-9 [16247011.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] J Gen Virol. 2006 Jul;87(Pt 7):1763-79 [16760381.001]
  • [Cites] J Virol. 2006 Jul;80(14):7037-51 [16809309.001]
  • [Cites] Nat Cell Biol. 2006 Aug;8(8):870-6 [16862143.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11594-9 [17178852.001]
  • [Cites] J Biol Chem. 2007 Jan 19;282(3):1595-606 [17079232.001]
  • [Cites] J Virol. 2007 Feb;81(3):1072-82 [17108053.001]
  • [Cites] J Virol. 2007 Mar;81(5):2524-30 [17151105.001]
  • [Cites] J Virol. 2007 May;81(10):5407-12 [17360761.001]
  • [Cites] Mol Cancer. 2007;6:28 [17433107.001]
  • [Cites] J Virol. 2007 Jun;81(12):6389-401 [17409162.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e89 [17542650.001]
  • [Cites] Cell. 2007 Oct 5;131(1):46-57 [17923087.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9954-62 [17942928.001]
  • [Cites] Cell Host Microbe. 2007 Jun 14;1(4):275-86 [18005708.001]
  • [Cites] J Biol Chem. 2007 Dec 14;282(50):36177-89 [17942393.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):823-37 [18082607.001]
  • [Cites] Nat Rev Microbiol. 2008 Mar;6(3):211-21 [18264117.001]
  • [Cites] Oncogene. 2008 May 8;27(21):3054-9 [18037959.001]
  • [Cites] J Virol. 2008 Jun;82(11):5127-36 [18353941.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):626-33 [18488044.001]
  • [Cites] Mol Biol Cell. 2009 Jan;20(1):296-305 [18923144.001]
  • [Cites] Genes Dev. 2001 Feb 15;15(4):428-43 [11230151.001]
  • (PMID = 19584288.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / P01 DE019085; United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / T32 CA108459-03; None / None / / R01 CA111185-01; United States / NCI NIH HHS / CA / CA114575-S1; None / None / / P30 CA093373-010001; United States / NCI NIH HHS / CA / CA108459-02; None / None / / R01 CA111185-04; United States / NCI NIH HHS / CA / CA111185; None / None / / P01 DE019085-010002; United States / NCI NIH HHS / CA / R01 CA111185-04; United States / NCI NIH HHS / CA / CA108459-01A2; United States / NCI NIH HHS / CA / CA108459-03; United States / NCI NIH HHS / CA / T32 CA108459-01A2; United States / NIDCR NIH HHS / DE / DE019085; United States / NCI NIH HHS / CA / R01 CA114575; None / None / / R01 CA111185-02; United States / NCI NIH HHS / CA / R01 CA111185-03; United States / NCI NIH HHS / CA / R01 CA111185-02; None / None / / R01 CA111185-03; United States / NCI NIH HHS / CA / T32 CA108459-02; United States / NCI NIH HHS / CA / R01 CA111185-05; United States / NCI NIH HHS / CA / R01 CA111185; United States / NIDCR NIH HHS / DE / P01 DE019085-020002; United States / NIDCR NIH HHS / DE / P01 DE019085-010002; United States / NCI NIH HHS / CA / R01 CA111185-01; United States / NCI NIH HHS / CA / T32 CA108459; United States / NIDCR NIH HHS / DE / DE019085-020002; United States / NCI NIH HHS / CA / CA111185-05; United States / NCI NIH HHS / CA / P30 CA093373-010001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / Repressor Proteins; 0 / Rta protein, Human herpesvirus 8; 0 / Small Ubiquitin-Related Modifier Proteins; 0 / TRIM28 protein, human; 0 / Trans-Activators; 0 / Viral Proteins; 147336-22-9 / Green Fluorescent Proteins; 452VLY9402 / Serine; EC 2.7.- / Protein Kinases
  • [Other-IDs] NLM/ NIHMS119615; NLM/ PMC2731626
  •  go-up   go-down


36. Spina M, Gloghini A, Tirelli U, Carbone A: Therapeutic options for HIV-associated lymphomas. Expert Opin Pharmacother; 2010 Oct;11(15):2471-81
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients.
  • [MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / trends. Boronic Acids / therapeutic use. Bortezomib. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / drug therapy. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Pyrazines / therapeutic use. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726820.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 0 / ofatumumab; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


37. Zong JC, Kajumbula H, Boto W, Hayward GS: Evaluation of global clustering patterns and strain variation over an extended ORF26 gene locus from Kaposi's sarcoma herpesvirus. J Clin Virol; 2007 Sep;40(1):19-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Direct DNA PCR sequencing was carried out on 136 distinct Kaposi's sarcoma and primary effusion lymphoma-related samples from different geographic locations.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 2004 Jan;85(Pt 1):155-63 [14718630.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):722-3 [7885137.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Clin Microbiol. 1996 Oct;34(10):2635-8 [8880542.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] Am J Epidemiol. 1998 Feb 1;147(3):217-21 [9482495.001]
  • [Cites] J Virol. 1999 May;73(5):4156-70 [10196312.001]
  • [Cites] J Virol. 1999 Aug;73(8):6646-60 [10400762.001]
  • [Cites] Intervirology. 2006;49(3):133-43 [16428889.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:1-42 [17089792.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):2029-38 [10900042.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]
  • [Cites] J Clin Virol. 2007 Sep;40(1):1-8 [17698410.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):194-202 [11158187.001]
  • [Cites] J Clin Virol. 2002 Jan;23(3):119-48 [11595592.001]
  • [Cites] J Med Virol. 2002 Feb;66(2):235-40 [11782933.001]
  • (PMID = 17690010.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081400-040001; United States / NCI NIH HHS / CA / R01 CA081422; United States / NCI NIH HHS / CA / R01 CA081422-05; United States / NCI NIH HHS / CA / CA73585; United States / NCI NIH HHS / CA / R01 CA073585-10; United States / NCI NIH HHS / CA / P01 CA081400; United States / NIAID NIH HHS / AI / R01 AI024576; United States / NCI NIH HHS / CA / CA081422-05; United States / NCI NIH HHS / CA / CA81422; United States / NCI NIH HHS / CA / CA073585-10; United States / NCI NIH HHS / CA / CA081400-049001; United States / NCI NIH HHS / CA / R01 CA073585; United States / NCI NIH HHS / CA / P01 CA081400-040001; United States / NCI NIH HHS / CA / CA81400; United States / NCI NIH HHS / CA / P01 CA081400-049001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS30403; NLM/ PMC2043355
  •  go-up   go-down


38. Fujimuro M: [Kaposi's sarcoma-associated herpesvirus and mechanisms of oncogenesis]. Uirusu; 2006 Dec;56(2):209-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8), is well known to be responsible for Kaposi's sarcoma, the most common AIDS-related cancer.
  • KSHV is also associated with the B cell malignancies primary effusion lymphoma and multicentric Castleman's disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446670.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / E2F Transcription Factors; 0 / Receptors, Notch; 0 / Viral Proteins; 0 / Wnt Proteins
  • [Number-of-references] 47
  •  go-up   go-down


39. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R: Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells. Cancer Res; 2007 Jul 15;67(14):7003-10
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV).
  • These findings may have clinical applicability in the development of effective therapies for PEL or other KSHV-related malignancies.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638913.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


40. Sunil M, Reid E, Lechowicz MJ: Update on HHV-8-Associated Malignancies. Curr Infect Dis Rep; 2010 Mar;12(2):147-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human herpesvirus 8 (HHV-8) is the oncogenic virus associated with Kaposi's sarcoma (KS) and lymphoproliferative disorders, namely, primary effusion lymphoma and multicentric Castleman's disease.
  • This review summarizes the recent developments in the fields of virus transmission, molecular biology, and treatment of HHV-8-related neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2008 Feb;82(3):1518-25 [18032494.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Ann Intern Med. 2007 Dec 18;147(12):836-9 [18087054.001]
  • [Cites] Blood. 2008 May 1;111(9):4731-40 [18199825.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):182-8 [18234418.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1236-7 [18525275.001]
  • [Cites] Clin Infect Dis. 2008 Sep 1;47(5):684-8 [18652555.001]
  • [Cites] Transplantation. 2008 Sep 15;86(5):738-44 [18791457.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] J Clin Virol. 2009 Jan;44(1):81-3 [18835212.001]
  • [Cites] J Virol. 1999 May;73(5):4156-70 [10196312.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3279-81 [11050015.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] J Infect Dis. 2006 Apr 15;193(8):1054-62 [16544245.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Nat Genet. 2006 Jun;38 Suppl:S25-30 [16736021.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1352-60 [16828498.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Pathol Int. 2006 Oct;56(10):617-24 [16984619.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1078-88 [16991082.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1550-8 [17047149.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1129-35 [17154170.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536 [18234764.001]
  • [Cites] Am J Hematol. 2008 Jun;83(6):498-503 [18260115.001]
  • [Cites] Am J Transplant. 2008 Mar;8(3):707-10 [18261181.001]
  • [Cites] Am J Transplant. 2008 Apr;8(4):906-7 [18294348.001]
  • [Cites] J Virol. 2008 May;82(9):4235-49 [18305042.001]
  • [Cites] Virology. 2008 May 25;375(1):94-102 [18321555.001]
  • [Cites] Br J Haematol. 2008 May;141(4):559-61 [18341641.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):601-2 [18410904.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] AIDS. 2008 May 11;22(8):937-45 [18453853.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1006-12 [18469709.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):311-20 [18515794.001]
  • [Cites] AIDS. 2008 May 31;22(9):1019-28 [18520345.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1232-4 [18525273.001]
  • [Cites] Curr Opin Infect Dis. 2007 Apr;20(2):152-6 [17496573.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):199-207 [17570106.001]
  • [Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5297-9 [18854561.001]
  • [Cites] Semin Cancer Biol. 2008 Dec;18(6):423-36 [18948197.001]
  • [Cites] Int Urol Nephrol. 2009;41(3):679-85 [19009366.001]
  • [Cites] J Med Virol. 2008 Dec;80(12):2153-60 [19040293.001]
  • [Cites] Transplantation. 2009 Jan 27;87(2):157-63 [19155967.001]
  • [Cites] Mod Pathol. 2009 May;22(5):618-26 [19287457.001]
  • [Cites] J Infect Dis. 2009 Aug 1;200(3):430-8 [19534596.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1867-74 [19554030.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Br J Haematol. 2009 Nov;147(3):405-8 [19681885.001]
  • [Cites] J Korean Med Sci. 2009 Oct;24(5):970-4 [19795003.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3350-6 [17664482.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2360-70 [17699731.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1439-45 [17721201.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1352-3 [17898112.001]
  • [Cites] PLoS Pathog. 2007 Sep 7;3(9):1348-60 [17907806.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • (PMID = 20461118.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Pantanowitz L, Kuperman M, Goulart RA: Clinical history of HIV infection may be misleading in cytopathology. Cytojournal; 2010;7:7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a result, a broad range of conditions are frequently included in the differential diagnosis of HIV-related lesions.
  • Large atypical cells identified in his effusion were concerning for primary effusion lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1989 Sep;96(3):460-6 [2766805.001]
  • [Cites] J HIV Ther. 2009 Jun;14(2):41-7 [19839366.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):715-27 [6301296.001]
  • [Cites] Arch Pathol Lab Med. 1995 Sep;119(9):811-4 [7545386.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):425-31 [7726138.001]
  • [Cites] Pathol Res Pract. 1997;193(7):497-502 [9342756.001]
  • [Cites] Eur Respir J. 1997 Nov;10(11):2638-43 [9426107.001]
  • [Cites] Clin Chest Med. 1998 Jun;19(2):341-9 [9646985.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):451-4 [9839136.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):656-61 [10366147.001]
  • [Cites] Diagn Cytopathol. 2000 Nov;23(5):322-5 [11074626.001]
  • [Cites] Diagn Cytopathol. 2004 Jun;30(6):381-5 [15176023.001]
  • [Cites] J Med Assoc Thai. 2004 Sep;87 Suppl 2:S152-60 [16083180.001]
  • [Cites] Ann Thorac Surg. 2006 Jun;81(6):2037-43 [16731126.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Cytopathology. 2008 Apr;19(2):86-93 [17916096.001]
  • [Cites] J Thorac Imaging. 2008 May;23(2):138-41 [18520574.001]
  • [Cites] Ear Nose Throat J. 2008 Jul;87(7):374-5 [18633927.001]
  • [Cites] Oncology. 2008;74(3-4):167-76 [18714165.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] Diagn Cytopathol. 2009 May;37(5):353-4 [18973265.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):27-34 [19339937.001]
  • [Cites] AJR Am J Roentgenol. 1987 Jan;148(1):25-8 [3491519.001]
  • (PMID = 20607096.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2895884
  • [Keywords] NOTNLM ; AIDS / HIV / cytology / misleading
  •  go-up   go-down


42. Gasperini P, Barbierato M, Martinelli C, Rigotti P, Marchini F, Masserizzi G, Leoncini F, Chieco-Bianchi L, Schulz TF, Calabrò ML: Use of a BJAB-derived cell line for isolation of human herpesvirus 8. J Clin Microbiol; 2005 Jun;43(6):2866-75
Cellosaurus - a cell line knowledge resource. culture/stock collections - BREM (CVCL_8660) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Establishment of latently infected cell lines from primary effusion lymphomas (PEL) presently is the most efficient system for the propagation of clinical strains of human herpesvirus 8 (HHV-8) in culture.
  • BBF cells can be used to propagate HHV-8 from different biological samples as well as to clarify important issues related to virus-cell interactions in a context distinct from endothelial and PEL-derived cell lines.
  • [MeSH-minor] Burkitt Lymphoma. Cell Line, Tumor. Humans. Saliva / virology. Virus Cultivation. Virus Latency. Virus Replication

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - BBF (CVCL_8659) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1404-8 [10747115.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] AIDS. 2000 Jun 16;14(9):1123-33 [10894276.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] J Virol Methods. 2001 Feb;91(2):109-17 [11164492.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Front Biosci. 2002 Jan 1;7:d268-74 [11779700.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] J Virol. 2002 Nov;76(21):11024-32 [12368345.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] J Infect Dis. 1993 Nov;168(5):1273-7 [8228362.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):542-9 [8627015.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Lancet. 1997 Mar 1;349(9052):609-11 [9057733.001]
  • [Cites] J Virol. 1997 Sep;71(9):7083-7 [9261440.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):467-72 [9543444.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] J Virol. 1998 Oct;72(10):8143-9 [9733855.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1534-7 [10228077.001]
  • [Cites] J Virol. 1999 Jul;73(7):5894-902 [10364341.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):447-56 [10784388.001]
  • (PMID = 15956410.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1151914
  •  go-up   go-down


43. Braza JM, Sullivan RJ, Bhargava P, Pantanowitz L, Dezube BJ: Images in HIV/AIDS. Pericardial primary effusion lymphoma. AIDS Read; 2007 May;17(5):250-2
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in HIV/AIDS. Pericardial primary effusion lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Pericardial Effusion / pathology


44. Bryant A, Milliken S: Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant; 2008 May;14(5):601-2
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, AIDS-Related / therapy. Lymphoma, Primary Effusion / therapy. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410904.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


45. Boulanger E, Meignin V, Oksenhendler E: Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol; 2008 May;141(4):559-61
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Herpesviridae Infections / complications. Herpesvirus 8, Human. Lymphoma, Primary Effusion / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Bortezomib. Female. Humans. Lymphoma, AIDS-Related / drug therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341641.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


46. Crum-Cianflone NF, Wallace MR, Looney D: Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS; 2006 Jul 13;20(11):1567-9
Genetic Alliance. consumer health - Primary effusion lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Herpesviridae Infections / drug therapy. Herpesvirus 8, Human. Lymphoma, AIDS-Related / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847420.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36214
  • [Publication-type] Case Reports; Letter; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


47. Ripamonti D, Marini B, Rambaldi A, Suter F: Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS; 2008 Jun 19;22(10):1236-7
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Primary Effusion / drug therapy

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525275.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


48. Lim ST, Rubin N, Said J, Levine AM: Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab. Ann Hematol; 2005 Aug;84(8):551-2
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Lymphoma / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Herpesvirus 8, Human / isolation & purification. Humans. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Middle Aged. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / drug therapy. Pericardial Effusion / pathology. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800785.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


49. Cassoni A, Ali U, Cave J, Edwards SG, Ramsay A, Miller RF, Lee SM: Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol; 2008 Nov 10;26(32):5297-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Lymphoma, AIDS-Related / radiotherapy. Lymphoma, Primary Effusion / radiotherapy

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Bestawros A, Boulassel MR, Michel RP, Routy JP: HHV-8 linked to Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in a HIV-1-infected man. J Clin Virol; 2008 Jun;42(2):179-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HHV-8 linked to Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in a HIV-1-infected man.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma, Primary Effusion / virology. Sarcoma, Kaposi / virology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / virology. Adult. Humans. Male






Advertisement